|
|
Volumn 29, Issue SUPPL. 2, 2008, Pages 191-195
|
|
Systemic treatment of advanced colorectal cancer;Aktuelle therapie des metastasierten kolorektalen karzinoms
|
|
Author keywords
Biomarker; Chemotherapy; Colorectal cancer; K ras; Targeted therapy
|
|
Indexed keywords
BEVACIZUMAB;
CAPECITABINE;
CETUXIMAB;
EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY;
FLUOROURACIL;
FOLINIC ACID;
IRINOTECAN;
OXALIPLATIN;
PANITUMUMAB;
TUMOR MARKER;
ADVANCED CANCER;
CANCER CHEMOTHERAPY;
CANCER DIAGNOSIS;
CANCER EPIDEMIOLOGY;
CANCER PATIENT;
CANCER STAGING;
CANCER SURVIVAL;
CLINICAL TRIAL;
COLORECTAL CANCER;
CONFERENCE PAPER;
DRUG TARGETING;
GENE EXPRESSION;
GENE MUTATION;
GENETIC TRAIT;
HUMAN;
LIVER METASTASIS;
MONOTHERAPY;
ONCOGENE K RAS;
PATIENT SATISFACTION;
UNSPECIFIED SIDE EFFECT;
WILD TYPE;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC AGENTS;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
COLORECTAL NEOPLASMS;
DRUG DELIVERY SYSTEMS;
GENES, ERBB-1;
GENES, RAS;
HUMANS;
LIVER NEOPLASMS;
NEOPLASM STAGING;
PROGNOSIS;
SURVIVAL RATE;
|
|
EID: 57449106687
PISSN: 01728113
EISSN: None
Source Type: Journal
DOI: 10.1007/s00292-008-1071-6 Document Type: Conference Paper |
|
Times cited : (1)
|
|
References (21)
|
